IS2474B - Asýleraðar píperidínafleiður sem melanókortín-4-viðtakaverkar - Google Patents

Asýleraðar píperidínafleiður sem melanókortín-4-viðtakaverkar

Info

Publication number
IS2474B
IS2474B IS6901A IS6901A IS2474B IS 2474 B IS2474 B IS 2474B IS 6901 A IS6901 A IS 6901A IS 6901 A IS6901 A IS 6901A IS 2474 B IS2474 B IS 2474B
Authority
IS
Iceland
Prior art keywords
melanocortin
piperidine derivatives
receptor agonists
acylated piperidine
receptor
Prior art date
Application number
IS6901A
Other languages
English (en)
Icelandic (is)
Other versions
IS6901A (is
Inventor
Ujjainwalla Feroze
Chu Lin
T. Goulet Mark
Louridas Bonnie
Warner Daniel
J. Wyvratt Matthew
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS6901A publication Critical patent/IS6901A/is
Publication of IS2474B publication Critical patent/IS2474B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
IS6901A 2001-02-28 2003-07-31 Asýleraðar píperidínafleiður sem melanókortín-4-viðtakaverkar IS2474B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27225801P 2001-02-28 2001-02-28
US30011801P 2001-06-22 2001-06-22
PCT/US2002/005724 WO2002068388A2 (en) 2001-02-28 2002-02-25 Acylated piperidine derivatives as melanocortin-4 receptor agonists

Publications (2)

Publication Number Publication Date
IS6901A IS6901A (is) 2003-07-31
IS2474B true IS2474B (is) 2008-12-15

Family

ID=26955402

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6901A IS2474B (is) 2001-02-28 2003-07-31 Asýleraðar píperidínafleiður sem melanókortín-4-viðtakaverkar

Country Status (27)

Country Link
US (1) US6818658B2 (enExample)
EP (1) EP1383501B1 (enExample)
JP (2) JP4104983B2 (enExample)
KR (1) KR20030076716A (enExample)
CN (1) CN1633297A (enExample)
AT (1) ATE358481T1 (enExample)
AU (1) AU2002258414B2 (enExample)
BG (1) BG108132A (enExample)
BR (1) BR0207658A (enExample)
CA (1) CA2439152C (enExample)
CZ (1) CZ20032325A3 (enExample)
DE (1) DE60219295T2 (enExample)
EA (1) EA200300944A1 (enExample)
EE (1) EE05440B1 (enExample)
ES (1) ES2283550T3 (enExample)
GE (1) GEP20053710B (enExample)
HR (1) HRP20030668A2 (enExample)
HU (1) HUP0303376A3 (enExample)
IL (1) IL157253A0 (enExample)
IS (1) IS2474B (enExample)
MX (1) MXPA03007785A (enExample)
NO (1) NO20033812L (enExample)
NZ (1) NZ527364A (enExample)
PL (1) PL210793B1 (enExample)
RS (1) RS63203A (enExample)
SK (1) SK286917B6 (enExample)
WO (1) WO2002068388A2 (enExample)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
JP4323169B2 (ja) * 2001-02-28 2009-09-02 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
ATE411021T1 (de) 2001-07-18 2008-10-15 Merck & Co Inc Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004024720A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
MY134457A (en) * 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US6998488B2 (en) 2003-03-10 2006-02-14 Merck & Co., Inc. Process and intermediates for the preparation of 4-aryl piperidines
US7276520B2 (en) 2003-03-26 2007-10-02 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
AR044510A1 (es) * 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
US7049323B2 (en) 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
AU2004259717A1 (en) * 2003-07-22 2005-02-03 Merck & Co., Inc. Piperidine derivatives as melanocortin-4 receptor agonists
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US7989634B2 (en) 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
GB0402492D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2560314A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
CN1984662A (zh) * 2004-07-16 2007-06-20 默克公司 用作黑皮质素－4受体激动剂的酰基化哌啶衍生物
DE602005018779D1 (de) 2004-07-19 2010-02-25 Merck & Co Inc Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten
CA2575736A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20080085885A1 (en) * 2004-08-13 2008-04-10 Linda Bristow Inhibition Of Voluntary Ethanol Consumption With Non-Peptidyl Melanocortin-4 Receptor Agonists
US20080021067A1 (en) * 2004-10-05 2008-01-24 Linda Bristow Methods For The Treatment Of Substance Abuse And Addiction
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006049933A2 (en) * 2004-10-29 2006-05-11 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
BRPI0518241A (pt) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
WO2006057904A1 (en) * 2004-11-23 2006-06-01 Merck & Co., Inc. Stereoselective preparation of 4-aryl piperidine amides by asymmetric hydrogenation of a prochiral enamide and intermediates of this process
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
US8129413B2 (en) 2005-06-27 2012-03-06 Merck Sharp & Dohme Corp. Crystalline forms of MC4R agonist and process for synthesis
KR20080047375A (ko) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20100160306A1 (en) * 2005-09-30 2010-06-24 Bakshi Raman K Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
WO2007047496A2 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
JP5243274B2 (ja) * 2006-02-23 2013-07-24 ファイザー・リミテッド ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン
EA200801738A1 (ru) * 2006-02-23 2008-12-30 Пфайзер Лимитед Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
EP2062878A4 (en) * 2006-08-30 2010-09-08 Shionogi & Co HYDRAZINE AMIDE DERIVATIVE
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
CA2673359A1 (en) * 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
JP2012512221A (ja) * 2008-12-16 2012-05-31 エフ．ホフマン−ラ ロシュ アーゲー ピロリジン−３−カルボン酸の製造方法
EP2389374A1 (en) 2009-01-20 2011-11-30 Pfizer Inc. Substituted pyrazinone amides
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2010089685A1 (en) 2009-02-03 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2393811A1 (en) 2009-02-04 2011-12-14 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2480551A1 (en) 2009-09-23 2012-08-01 Pfizer Inc. Gpr 119 modulators
ME02016B (me) 2009-11-02 2015-05-20 Pfizer Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
CA2778316A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP2013510834A (ja) 2009-11-16 2013-03-28 メリテク ［１，５］‐ジアゾシン誘導体
CA2780463A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
HUE025774T2 (en) 2010-03-19 2016-05-30 Pfizer 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011158149A1 (en) 2010-06-18 2011-12-22 Pfizer Inc. 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PL2632925T3 (pl) 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
MX2013009140A (es) 2011-02-08 2013-10-01 Pfizer Moduladores del receptor de glucagon.
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EA022375B1 (ru) 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
EP2731944A1 (en) 2011-07-15 2014-05-21 Pfizer Inc Gpr 119 modulators
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3055300B1 (en) 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
AU2015245260A1 (en) 2014-04-10 2016-10-06 Pfizer Inc. 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
MX386063B (es) * 2014-05-29 2025-03-18 Mitsubishi Tanabe Pharma Corp Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
TN2017000485A1 (en) 2015-06-17 2019-04-12 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
RU2696269C1 (ru) 2015-12-29 2019-08-01 Пфайзер Инк. Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JP2020500838A (ja) 2016-10-14 2020-01-16 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ Α−アミノ−β−カルボキシムコン酸セミアルデヒドデカルボキシラーゼの阻害剤
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020044266A1 (en) 2018-08-31 2020-03-05 Pfizer Inc. Combinations for treatment of nash/nafld and related diseases
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP7467510B2 (ja) * 2019-11-07 2024-04-15 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
US20240059652A1 (en) * 2020-12-22 2024-02-22 Lg Chem, Ltd. Amorphous melanocortin receptor agonist and method for preparing same
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
JP2001526178A (ja) 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
WO2000074649A2 (en) 1999-06-03 2000-12-14 Maxim Pharmaceuticals, Inc. Ophthalmic histamine compositions and uses thereof
JP2003505435A (ja) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
SK11452002A3 (sk) * 2000-02-11 2003-03-04 Vertex Pharmaceuticals Incorporated Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov
US6458790B2 (en) 2000-03-23 2002-10-01 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
JP4323169B2 (ja) * 2001-02-28 2009-09-02 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use

Also Published As

Publication number Publication date
SK286917B6 (sk) 2009-07-06
CA2439152C (en) 2008-06-17
EP1383501A2 (en) 2004-01-28
AU2002258414B2 (en) 2005-12-15
EP1383501A4 (en) 2005-10-12
PL372160A1 (en) 2005-07-11
EP1383501B1 (en) 2007-04-04
DE60219295D1 (de) 2007-05-16
WO2002068388A2 (en) 2002-09-06
DE60219295T2 (de) 2008-01-03
JP2004529105A (ja) 2004-09-24
HRP20030668A2 (en) 2005-08-31
ES2283550T3 (es) 2007-11-01
CA2439152A1 (en) 2002-09-06
IS6901A (is) 2003-07-31
HUP0303376A3 (en) 2007-08-28
RS63203A (sr) 2006-12-15
NO20033812L (no) 2003-10-28
ATE358481T1 (de) 2007-04-15
JP2008150394A (ja) 2008-07-03
US6818658B2 (en) 2004-11-16
GEP20053710B (en) 2005-12-26
KR20030076716A (ko) 2003-09-26
CN1633297A (zh) 2005-06-29
NO20033812D0 (no) 2003-08-27
US20030225060A1 (en) 2003-12-04
EA200300944A1 (ru) 2004-04-29
CZ20032325A3 (cs) 2004-02-18
MXPA03007785A (es) 2003-12-08
PL210793B1 (pl) 2012-03-30
BR0207658A (pt) 2005-10-25
SK10872003A3 (sk) 2004-02-03
NZ527364A (en) 2004-12-24
EE05440B1 (et) 2011-08-15
IL157253A0 (en) 2004-02-19
JP4104983B2 (ja) 2008-06-18
BG108132A (bg) 2004-12-30
EE200300415A (et) 2003-12-15
WO2002068388A3 (en) 2003-03-13
HUP0303376A2 (hu) 2004-01-28
JP5094453B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
IS2474B (is) Asýleraðar píperidínafleiður sem melanókortín-4-viðtakaverkar
ATE430565T1 (de) Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
ATE341327T1 (de) Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
TW200508223A (en) Acylated piperazine derivatives as melanocortin-4 receptor agonists
DE60229393D1 (de) Überbrückte piperidinderivate als melanocortin-rezeptor-agonisten
DE602004028228D1 (de) Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
MXPA05010724A (es) Derivados de las espiropiperidinas aciladas como agonistas del receptor de la melanocortina-4.
WO2005009950A3 (en) Piperidine derivatives as melanocortin-4 receptor agonists
NO20082011L (no) Acylerte spiropiperidinderivater som melanocortin-4-reseptormodulatorer
WO2008039418A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor modulators
WO2007041061A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE454148T1 (de) Acylierte piperidinderivative als melanocortin-4- rezeptoragonisten
WO2007047496A3 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2006019787A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
JO2351B1 (en) Derived bipridine derivatives as cofactors of melanocortin-4 receptor